NCT05983237View on ClinicalTrials.gov

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Melanoma
Interventions
DRUG

Fluzoparib Camrelizumab Temozolomide

Fluzoparib 50-150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w Temozolomide 50mg/m2-200mg/m2 d1-5,q3w

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Jun Guo

OTHER